An in vivo study was performed to establish and validate the bioavailability of organic elemental iron (BioIron) in combination with or without BioPerine®.
The study involved a single oral dose of BioIron with BioPerine® (group I) or BioIron without BioPerine® (group II) administration to rabbits, and blood samples were collected at different time points.
Results showed that at 8 h time point, serum concentration of iron was significantly higher in group treated with BioIron containing BioPerine® (36.55±9.97 μg/ml) when compared to group treated with BioIron containing no BioPerine®.
In an open-label, non-randomized study, 30 subjects were provided with BioIron™ tablet (containing 8.5 mg of elemental iron and 2.5 mg of BioPerine® ) twice a day as a dietary supplement for a period of 56 days.
It was evident that treatment of iron deficiency anemia with BioIron™ for 56 days showed a statistically significant increase in hematologic values. Blood hemoglobin level was improved significantly. A significant improvement in serum iron (could be correlated to the immediate release of iron from BioIron™ into the systemic circulation); total iron binding capacity and serum ferritin level was also observed (Fig. 1 and 2).
Overall, BioIron™ was safe and effective in the management of iron deficiency anemia without any adverse events.